@article {8166,
	title = {A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix},
	journal = {Cancer},
	volume = {79},
	year = {1997},
	note = {Cited By :26Export Date: 21 February 2017},
	month = {1997},
	pages = {2391 - 2395},
	abstract = {BACKGROUND. Patients with metastatic carcinoma of the uterine cervix have limited survival. Thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. METHODS. Twenty-seven patients with Stage IV primary or recurrent carcinoma of the uterine cervix were assigned to chemotherapy treatment at 4-week intervals with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The treatment was comprised of methotrexate, 30 mg/m2 administered intravenously (i.v.) on Days 1, 15, and 22; vinblastine, 3 mg/m2 i.v. on Days 2, 15, and 22; doxorubicin, 30 mg/m2 i.v. on Day 2; and cisplatin, 70 mg/m2 i.v. on Day 2. Granulocyte-colony stimulating factor (G-CSF) was given subcutaneously on Days 6-10 at a dose of 5 μg/kg. RESULTS. After a median of 4 cycles (a maximum of 6 in responders), the authors observed objective responses in 14 patients (52\%), including 3 complete responses (11\%) and 11 partial responses (41\%). Median overall survival was 11 months (range, 4-15+ months), and median progression free survival of the responders was 8 months (range, 6-15+ months). Toxicity was acceptable and included neutropenia, alopecia, vomiting, and stomatitis. CONCLUSIONS. MVAC is an active regimen in the treatment of patients with advanced or recurrent carcinoma of the uterine cervix. It produced responses in one-half of the patients in this study, and it can be administered on an outpatient basis. The addition of G-CSF appears to reduce hematologic toxicity.},
	keywords = {Cervical carcinoma, Chemotherapy, Metastatic, Recurrent},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030953995\&doi=10.1002\%2f\%28SICI\%291097-0142\%2819970615\%2979\%3a12\%3c2391\%3a\%3aAID-CNCR14\%3e3.0.CO\%3b2-M\&partnerID=40\&md5=57e3e1208557680c83caa04f9e9f864e},
	author = {Papadimitriou, C.A. and Dimopoulos, M.A. and Giannakoulis, N. and Sarris, K. and Vassilakopoulos, G. and Akrivos, T. and Voulgaris, Z. and Vlahos, G. and Diakomanolis, E. and Michalas, S.}
}
